{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:20:50Z","timestamp":1783056050311,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFE0201700"],"award-info":[{"award-number":["2020YFE0201700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172086"],"award-info":[{"award-number":["82172086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejpb.2026.115097","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:28:34Z","timestamp":1777930114000},"page":"115097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Decoupling efficacy from toxicity: Inhalable liposomal nintedanib for safe and effective treatment of pulmonary fibrosis"],"prefix":"10.1016","volume":"224","author":[{"given":"Xinxin","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxiong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muse","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0978-2363","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejpb.2026.115097_b0005","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis [J]","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030593","article-title":"Idiopathic pulmonary fibrosis and lung cancer: Mechanisms and molecular targets [J]","volume":"20","author":"Ballester","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115097_b0015","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.202311-2101OC","article-title":"Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease [J]","volume":"210","author":"Khor","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2026.115097_b0020","first-page":"603","article-title":"Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease [Z]","author":"Marinescu","year":"2024","journal-title":"BMJ Publishing Group Ltd."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115097_b0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: State of the art for 2023 [J]","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1513\/AnnalsATS.201806-376RL","article-title":"Potential delays in diagnosis of idiopathic pulmonary fibrosis in Medicare beneficiaries [J]","volume":"16","author":"Mooney","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejpb.2026.115097_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-017-0560-x","article-title":"Barriers to timely diagnosis of interstitial lung disease in the real world: The INTENSITY survey [J]","volume":"18","author":"Cosgrove","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejpb.2026.115097_bib206","doi-asserted-by":"crossref","unstructured":"JJiang, S., Li, H., Zhang, L., Mu, W., Zhang, Y., Chen, T., Wu, J., Tang, H., Zheng, S., Liu, Y., Wu, Y., Luo, X., Xie, Y., & Ren, J. (2025). Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic acids Res., 53(D1), D1670\u2013D1676. https:\/\/doi.org\/10.1093\/nar\/gkae973.","DOI":"10.1093\/nar\/gkae973"},{"issue":"9807","key":"10.1016\/j.ejpb.2026.115097_b0040","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis [J]","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115097_b0045","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis [J]","volume":"208","author":"Wynn","year":"2011","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115097_b0050","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a Selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis [J]","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115097_b0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612033392341","article-title":"Re-evaluation of fibrogenic cytokines in lung fibrosis [J]","volume":"9","author":"Kelly","year":"2003","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115097_b0060","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis [J]","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115097_b0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases [J]","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115097_b0070","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/resp.13002","article-title":"Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia [J]","volume":"22","author":"Dowman","year":"2017","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115097_b0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: A randomised controlled trial [J]","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax"},{"issue":"161","key":"10.1016\/j.ejpb.2026.115097_b0080","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0017-2021","article-title":"Lung transplantation for interstitial lung disease [J]","volume":"30","author":"Kapnadak","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines [J]","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115097_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106047","article-title":"Rod-shaped nintedanib nanocrystals improved oral bioavailability through multiple intestinal absorption pathways [J]","volume":"168","author":"Zhu","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115097_b0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","volume":"41","author":"Stopfer","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2026.115097_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications [J]","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy: a review [J]","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115097_b0110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/ph17081059","article-title":"Nanoparticle-based drug delivery systems in inhaled therapy: Improving respiratory medicine [J]","volume":"17","author":"Cojocaru","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.drudis.2014.09.020","article-title":"Recent advances in controlled pulmonary drug delivery [J]","volume":"20","author":"Liang","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115097_b0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1208\/s12249-023-02559-y","article-title":"Inhalable nanoparticle-based dry powder formulations for respiratory diseases: Challenges and strategies for translational research [J]","volume":"24","author":"Chan","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115097_b0125","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17476348.2021.1875821","article-title":"Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection [J]","volume":"15","author":"Zhang","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"issue":"161","key":"10.1016\/j.ejpb.2026.115097_b0130","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2021","article-title":"Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections [J]","volume":"30","author":"Chalmers","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115097_b0135","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1038\/s41467-025-58312-5","article-title":"Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2026.115097_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114655","article-title":"Inhalable stealth liposomes improve peptide delivery for pulmonary fibrosis treatment","volume":"391","author":"Lin","year":"2026","journal-title":"J. Control. Release"},{"issue":"35","key":"10.1016\/j.ejpb.2026.115097_b0145","first-page":"31656","article-title":"Harnessing surface hydrophilicity of inhalable nanoparticles for precision delivery of glucagon-like peptide-1 receptor agonists or anti-asthmatic therapeutics","volume":"19","author":"Liu","year":"2025","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115097_b0150","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a hightly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy[J]","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2026.115097_b0155","doi-asserted-by":"crossref","unstructured":"Momtazi-Borojeni A A, Abdollahi E, Jaafari M R, et al. Protective effects of anionic nanoliposomes on hyperlipidemia and atherosclerosis progression in a rabbit model[J]. European Heart Journal, 2020(Supplement 2): Supplement 2.DOI:10.1093\/ehjci\/ehaa946.2995.","DOI":"10.1093\/ehjci\/ehaa946.2995"},{"key":"10.1016\/j.ejpb.2026.115097_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114134","article-title":"The role of PEGylation in the pulmonary delivery of antifibrotic liposomal therapies","volume":"386","author":"Pi\u00f1ol-Cancer","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115097_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102201","article-title":"Harnessing self-assembled nanoplatform of Dexamethasone and \u03b1-linolenic acid for high-efficiency inhibition of pulmonary cytokine storm and fibrosis in mice[J]","volume":"55","author":"Liu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.ejpb.2026.115097_b0165","volume":"7(1):3458","author":"Zhao","year":"2017","journal-title":"Pharmacodynamic and Pharmacokinetic Assessment of Pulmonary Rehabilitation Mixture for the Treatment of Pulmonary Fibrosis[j].rep"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115097_b0170","first-page":"1251","article-title":"miR-29 Inhibits bleomycin-induced pulmonary fibrosis in mice[J].Molecular therapy the journal of the American society of","volume":"20","author":"Xiao","year":"2012","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115097_b0175","first-page":"92","article-title":"IL-12 attenuates bleomycin-induced pulmonary fibrosis[J]","volume":"281","author":"Keane","year":"2001","journal-title":"American J Phys Lung Cellular Molecular Phys"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115097_b0180","first-page":"12","article-title":"Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19[J]","volume":"16","author":"Li","year":"2021","journal-title":"Asian Pharmaceutical Sci"},{"issue":"18","key":"10.1016\/j.ejpb.2026.115097_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv9571","article-title":"Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis[J]","volume":"11","author":"Chen","year":"2025","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115097_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70023","article-title":"Lysosomal acidification: A new perspective on the pathogenesis and treatment of pulmonary fibrosis[J]","volume":"15","author":"Tian","year":"2025","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115097_b0195","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2006.12.002","article-title":"Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? [J]","volume":"118","author":"Cui","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115097_b0200","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:03:19Z","timestamp":1783054999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"alternative-id":["S0939641126001189"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115097","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoupling efficacy from toxicity: Inhalable liposomal nintedanib for safe and effective treatment of pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115097"}}